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AbsTrACT
Aim To show the characteristics and outcomes 
of patients with neovascular age- related macular 
degeneration (nAMD) who had extended remission (ER) 
while on a pro re nata (PRN) treatment protocol.
Methods This was a retrospective case–control 
study of a consecutive series of patients with nAMD 
treated with a PRN antivascular endothelial growth 
factor (anti- VEGF) drug regimen. ER was defined as 
the absence of haemorrhage, intraretinal/subretinal 
fluid on optical coherence tomography and leakage on 
fluorescein angiography for 52 weeks after cessation of 
anti- VEGF therapy. Matching patients with nAMD who 
did not achieve ER were included as control group. Cox 
regression analysis was fitted to identify predictors of 
time to achieve ER and time to recurrence. A logistic 
regression analysis of baseline characteristics was used 
to identify predictors of achieving ER.
results Of 830 eyes treated with anti- VEGF 
monotherapy, 77 (9.2%) eyes achieved ER during a 
median follow- up of 236 weeks (range 70–525 weeks). 
Cox regression analysis showed that ER was achieved 
earlier in eyes with isolated intraretinal fluid (HR, 2.05; 
95% CI 1.929 to 4.520; p=0.045) at presentation. 
Logistic regression analysis showed that type 3 choroidal 
neovascularisation (OR, 0.090; 95% CI 0.021 to 0.382; 
p=0.001), thinner choroid (OR, 0.993; 95% CI 0.988 to 
0.998; p=0.004) and absence of macular atrophy (OR, 
0.233; 95% CI 0.065 to 0.839; p=0.026) at baseline 
increased the likelihood of achieving ER.
Conclusion ER is achievable in 9.2% of patients under 
PRN therapy for nAMD. At presentation with nAMD, 
anatomical features on retinal imaging may predict the 
likelihood of achieving ER and a shorter time to achieve ER.
InTroduCTIon
Age- related macular degeneration (AMD) is the 
major cause of blindness in elderly people in indus-
trialised countries.1 The estimated prevalence of 
late AMD among the elderly people in the USA is 
0.8%.2 The number of legally blind people in the 
world is expected to be 2.0 million, and 8.8 million 
people will have moderate and severe vision loss 
due to late AMD in 2020.3
The advent of antivascular endothelial growth 
factor (anti- VEGF) agents has improved the clin-
ical outcomes of patients with neovascular AMD 
(nAMD), as shown in the pivotal Anti- VEGF Anti-
body for the Treatment of Predominantly Classic 
Choroidal Neovascularization in AMD (ANCHOR) 
and Minimally Classic/Occult Trial of the Anti- 
VEGF Antibody Ranibizumab in the Treatment 
of Neovascular AMD (MARINA) clinical trials.4–8 
Numerous other studies such as Comparison of 
AMD Treatments Trials (CATT), VEGF Trap- Eye: 
Investigation of Efficacy and Safety in Wet AMD 
(VIEW) and Lucentis Compared to Avastin Study 
(LUCAS) have suggested that regular therapy to 
eliminate subretinal vascular leakage improves 
visual outcomes. Treatment regimens currently 
used include pro re nata (PRN) and ‘treat and 
extend’ (TAE) regimens, which are commonly used 
to reduce treatment burden for both patients and 
doctors.9–13
The PrONTO study showed similar outcomes 
between monthly dosing and a PRN regimen, with 
fewer intravitreal injections over 2 years.14 The 
IVAN study also provided equivalent effect between 
monthly and as- needed groups at year 1 and year 
2.15–17 Although the CATT study demonstrated 
that the mean gain in visual acuity was greater for 
monthly than for as- needed treatment in year 2, 
there was no statistically significant difference in 
visual acuity or morphological outcomes between 
drug or regimen groups in year 5.11 18
A prospective trial of TAE versus monthly dosing 
of intravitreal ranibizumab for nAMD provided 
comparable results between the two groups at 1 
year.19 Gupta et al20 also reported that TAE regimen 
showed favourable visual outcomes with fewer 
patient visits, fewer treatments and lower medical 
costs compared with monthly injections, but more 
injections compared with the PrONTO study.
Compared with a PRN treatment regimen, the 
maximal length of treatment interval between 
injections using the TAE regimen is typically 12 
weeks.20 21 Therefore, patients have to continue 
to receive maintenance injections at least every 12 
weeks regardless of disease activity when using TAE 
regimen. In our experience using PRN therapy, some 
patients show absent retinal exudation for much 
longer intervals after injections are discontinued 
and may not need retreatment for intervals well 
over the typical 3- month TAE maximum interval.22 
For these patients, the PRN regimen would be much 
less burdensome than the TAE regimen23 and would 
also decrease cost and the risk of complications. In 
addition, a true PRN regimen is the only way to 
determine if some eyes will not require ongoing 
maintenance treatment. It has been suggested that, 
in a small group of patients who met predefined exit 
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criteria, treatment may be discontinued with a low incidence of 
recurrences.24 Similarly, in the CATT 5- year follow- up study, 96 
patients (14.8%) received no treatments between the end of the 
2- year clinical trial and the 5- year CATT follow- up study visit.11 
However the CATT study terminated after 2 years. The IVAN 
study likewise found that the PRN strategy was non- inferior to 
monthly treatment.17 In another retrospective study of the PRN 
treatment in Japan, 81 of 236 eyes (34.3%) and 35 of 139 eyes 
(25.2%) had no recurrence after three loading anti- VEGF injec-
tions in year 1 and year 2, separately.25 However, Asian eyes may 
have different responses from the typical US population.
Previously, we reported the results of a small study evalu-
ating 6- month remissions without anti- VEGF therapy and found 
certain predictors of this duration of remission.22 Our purpose 
in this study was to evaluate a larger population with longer 
follow- up, and to evaluate the predictors and prevalence of over 
1- year (extended) remission in eyes treated with PRN anti- VEGF 




This was a retrospective chart review of treatment- naïve patients 
with newly diagnosed nAMD seen at the Jacobs Retina Center 
and Shiley Eye Institute, University of California San Diego.
study population
The charts of all patients with nAMD seen over a 10- year period 
between 2008 and 2018 were reviewed. The inclusion criteria of 
the remission group were (1) new- onset nAMD at presentation, 
(2) age >50 years, (3) three consecutive monthly bevacizumab 
or ranibizumab (Genentech, San Francisco, California, USA) 
injections followed by as- needed treatment regimen, (4) remis-
sion time ≥52 weeks at any time point during follow- up, and (5) 
best- corrected visual acuity (BCVA) of 20/160 or better at the 
final visit. Eyes were excluded in the presence of (1) a central 
disciform scar, (2) central geographic atrophy, (3) concomitant 
ocular diseases (ie, diabetic retinopathy, glaucoma, retinal vein 
occlusion, uveitis or epiretinal membrane), (4) choroidal neovas-
cularisation (CNV) secondary to causes other than AMD (ie, 
myopic CNV, angioid streaks or other secondary CNV), (5) a 
history of vitrectomy, laser treatment or photodynamic therapy 
(PDT), or (6) monocular status. Only binocular patients were 
included in this study, as continuous monthly or every-8- week 
intravitreal anti- VEGF injections were given to monocular 
patients.
A group of patients with new- onset nAMD treated with 
as- needed anti- VEGF therapy without extended remission (ER) 
matched for age, gender, ethnicity, baseline BCVA and follow- up 
time were included as the control group. Baseline presentation 
features were compared between the remission and the control 
groups.
ophthalmological examination and retinal imaging
All patients underwent a complete ophthalmological examina-
tion and retinal imaging at baseline (on diagnosis of nAMD) and 
at each follow- up visit, including BCVA measurement using the 
ETDRS chart, slit- lamp biomicroscopy and indirect ophthalmo-
scopy through dilated pupils.
Retinal imaging was performed, including fluorescein angiog-
raphy (FA) and high- resolution spectral domain optical coher-
ence tomography (SD- OCT) using a device coupled with a 
simultaneous confocal scanning laser ophthalmoscopy (cSLO) 
(Spectralis HRA+OCT, Heidelberg Engineering, Carlsbad, Cali-
fornia, USA). As a routine imaging protocol, raster SD- OCT 
scans along with horizontal and vertical B- scans through the 
fovea, as well as through other areas where CNV activity was 
most pronounced, were acquired.
Treatment protocol
Intravitreal anti- VEGF treatment was started when the SD- OCT 
showed exudation involving the fovea, with either intraretinal 
or subretinal fluid (IRF/SRF) accompanied by leakage on FA. 
Pigment epithelial detachments (PED) in the absence of IRF or 
SRF were not treated.
The standard protocol employed for the treatment of nAMD 
and macular fluid was three loading intravitreal injections of 
bevacizumab (1.25 mg/0.05 mL) or ranibizumab (0.5 mg/0.05 
mL) given at 4- week intervals and under SD- OCT and FA guid-
ance. Injections were continuously given at 4- week intervals until 
the retina became completely dry, after which an observation 
phase was initiated. Patients were followed at 4, 8 and 12 weeks 
from the last injection, followed by a visit every 24 weeks there-
after. Patients were given precautions regarding warning signs, 
including decline in vision and worsening metamorphopsia, with 
instructions to follow up immediately if any of these are noted.
The same treatment regimen was resumed when there was 
evidence of recurrence of exudation as we have previously 
reported.25 26 Recurrence was defined as new IRF and/or SRF on 
SD- OCT and leakage on FA accompanied by symptoms of wors-
ening, including decline in ETDRS BCVA or presence of meta-
morphopsia. Resolution was defined as the absence of leakage 
on FA and complete absence of IRF and SRF on SD- OCT.
Eyes that demonstrated treatment resistance or non- response 
to bevacizumab or ranibizumab were shifted to aflibercept 
(Regeneron, Tarrytown, New York, USA) 2.0 mg/0.05 mL since 
2012, when aflibercept became available. Treatment resistance 
was defined as having multiple recurrences (minimum of two 
recurrences after the eyes have been completely dry following 
a series of at least 3- monthly injections per treatment cycle), or 
persistence of exudation (poor response to monthly ranibizumab 
or bevacizumab injections for at least 5 months) as evident on 
clinical examination and on imaging studies (leakage on FA, or 
fibrovascular PED with IRF and/or SRF on SD- OCT) while on 
monthly ranibizumab or bevacizumab monotherapy.25 A dose- 
escalating regimen of aflibercept 2.0 mg/0.05 mL was given every 
8 weeks and escalated to every 4 weeks if needed, depending on 
clinical response.
Intravitreal injections were carried out under aseptic condi-
tions in the clinic. Preservative- free lidocaine gel was instilled 
in the superior fornix at least 5 min prior to the injection. A 
lid speculum was placed and 5% povidone iodine solution was 
instilled twice on the conjunctiva prior to injection. The lido-
caine gel was displaced by the povidone iodine. The pars plana 
was marked externally 3.5–4.0 mm from the limbus, depending 
on the lens status. The intravitreal injection was performed using 
a 30- gauge needle in the superotemporal or superonasal quad-
rant. Following the injection, eyes were thoroughly washed with 
sterile balanced salt solution. Topical antibiotic drops were not 
prescribed after the procedure.
data collection
The baseline demographic data collected from each patient’s 
record included age, gender, ethnicity, laterality of the involved 
eye, BCVA, lens status and duration of follow- up. Imaging 
parameters at baseline were measured by two experienced retina 
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Age, mean±SD 79.99±8.43 80.1±7.99 0.105
Female, n (%) 45 (58.4) 62 (61.9) 0.605
Ethnicity
Caucasian, n (%)




0.40±0.27 (20/50) 0.38±0.27 (20/48) 0.771
Duration of follow- up, median 
weeks (range)
236 (70–525) 222 (66–508) 0.104
BCVA, best- corrected visual acuity; logMAR, logarithm of minimum angle of 
resolution.
Figure 1 Kaplan- Meier curve showing the time to achieve extended 
remission from baseline. Figure 2 Kaplan- Meier curve of the survival time to recurrence after 
the last intravitreal injection.
specialists (TL and KCD), taking note of the CNV type (type 
1: subretinal pigment epithelium [RPE]; type 2: subretinal; 
type 3: retinal angiomatous proliferation (RAP)), CNV loca-
tion (subfoveal, juxtafoveal or extrafoveal), CNV lesion size, 
central foveal thickness, subfoveal choroidal thickness, fluid type 
(isolated SRF, isolated IRF, or combined SRF and IRF), presence 
of outer retinal tubulation, presence of macular atrophy, poste-
rior vitreous status (incomplete or complete posterior vitreous 
detachment) and PED type (serous, drusenoid or fibrovascular). 
CNV lesion size was measured as the maximum size of hyperflu-
orescence on late- phase FA. Macular atrophy was defined as loss 
of outer retinal layers and RPE with signal hypertransmission to 
the choroid in the macula. All measurements were done using 
the calliper function of the Spectralis’ built- in software.
statistical analysis
The Shapiro- Wilk test was used to test normality of distribution. 
The remission and control groups were analysed together in a 
logistic regression model to identify baseline anatomical factors 
that are predictive of ER. ETDRS visual acuities were converted 
to logarithm of the minimum angle of resolution (logMAR) for 
statistical analysis. Kaplan- Meier survival curves were gener-
ated for survival analysis. Univariate and multivariate Cox 
proportional hazard models were fitted for the time to achieve 
remission and time to recurrence. Significant variables obtained 
using univariate analysis were selected for the multivariate Cox 
regression. P values represent the results for two- sided tests, with 
values less than 0.05 considered statistically significant. Statis-
tical analyses were conducted using SPSS V.24.0.
resulTs
A total of 830 eyes of 558 patients with nAMD were identified 
during the study period. Of these, 77 eyes (9.2%) of 70 patients 
had ER at some time point during a median of 236 weeks (range 
70–525) follow- up. A random sample of 84 eyes of 70 patients 
were included as a matched control group. The baseline char-
acteristics are summarised in table 1. The groups were matched 
by age, gender, ethnicity, baseline visual acuity and duration of 
follow- up.
In the remission group, the median time needed to achieve 
ER after the initial anti- VEGF injection was 77 weeks (range 
12–466) (figure 1). The median number of anti- VEGF injections 
needed to achieve ER was 10 (range 3–56). Forty- one of the 
77 eyes (53.3%) were receiving bevacizumab (40) or ranibi-
zumab (1) prior to achieving ER, and 36 (46.8%) were receiving 
aflibercept injections prior to achieving ER. Thirty- two per cent 
of eyes (25 eyes) achieved ER during the first year of presen-
tation, 19.5% of eyes (15 eyes) at year 2, 19.5% of eyes (15 
eyes) at year 3, and 28.5% of eyes (22 eyes) after more than 3 
years of follow- up. The Kaplan- Meier analysis showed a median 
duration of total remission of 217 weeks (range 52–507 weeks) 
(figure 2). Sixty- four per cent remained dry and free of exuda-
tion at the final visit. Figure 3 illustrates the clinical picture of a 
patient who achieved ER.
Twenty- eight (36.4%) eyes recurred after a median remission 
period of 82 weeks (range 52–217). Of these recurrences, five 
(6.5% of remission group, or 17.9% of recurrences) had a haem-
orrhagic component, two of which were dense and involved 
the fovea, and the rest were thin and extrafoveal. There was a 
decline in vision from a median of 0.25 logMAR (range 0.0–0.9) 
(SE≅20/36) to 0.32 logMAR (range 0.0–1.0) (SE≅20/42). This 
change was not statistically significant (p=0.330).
Visual acuity remained stable in the remission group at a 
median of 0.32 logMAR (range 0–1.0) (Snellen≅20/42) from 
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Figure 3 Imaging tests of the left eye in an 82- year- old woman with 
new- onset nAMD. Visual acuity at presentation was 20/40. Baseline 
imaging confirmed the diagnosis of nAMD. Infrared photo (top left) 
showed RPE changes accompanied by a PED in the macula with 
corresponding mixed increased and decreased autofluorescence signal 
on FAF (middle left). Leakage was evident on late- phase FA (bottom 
Left). Horizontal sectional SD- OCT across the fovea at baseline (top 
right) showed subretinal fluid, subretinal hyper- reflective material 
and pigment migration overlying a large fibrovascular PED involving 
the fovea. Monthly intravitreal anti- VEGF treatment was initiated 
with bevacizumab (#9) and subsequently aflibercept (#5) until the 
retina was completely dry (sub- top right). The retina remained dry 
throughout the remainder of follow- up (middle- bottom right), a total 
duration of remission of 117 weeks. BCVA at the final visit was 20/25. 
BCVA, best- corrected visual acuity; FA, fluorescein angiography; FAF, 
fundus autofluorescence; nAMD, neovascular age- related macular 
degeneration; PED, pigment epithelial detachment; RPE, retinal pigment 
epithelium; SD- OCT, spectral domain optical coherence tomography; 
VEGF, vascular endothelial growth factor.
Table 2 Logistic regression analysis of clinical characteristics of 
remission and control groups at baseline
Variables or (95% CI) P value
CNV type
Type 3 1.0000
  Type 1 0.000 (0.000 to 0.000) 0.999
  Type 2 0.090 (0.021 to 0.382) 0.001
Fluid type
  SRF/IRF combined 1.0000
   Isolated IRF 0.665 (0.217 to 2.033) 0.151
   Isolated SRF 5.397×109 0.999
Posterior vitreous status
  Complete PVD 1.0000
  No PVD 9.171 (0.955 to 88.099) 0.055
  Incomplete PVD 0.974 (0.303 to 3.123) 0.964
PED
  Fibrovascular 1.0000
  Serous 4.154 (0.312 to 55.308) 0.281
  Drusenoid 1.559 (0.242 to 10.034) 0.64
CFT 0.999 (0.996 to 1.003) 0.688
SCT 0.993 (0.988 to 0.998) 0.004
Mean lesion size 0.962 (0.854 to 1.083) 0.519
ORT
  Absent 1.0000
  Present 0.247 (0.053 to 1.157) 0.076
Macular atrophy
  Absent 1.0000
  Present 0.233 (0.065 to 0.839) 0.026
CFT, central foveal thickness; CNV, choroidal neovascularisation; IRF, intraretinal 
fluid;ORT, outer retinal tubulation; PED, pigment epithelium detachment; PVD, 
posterior vitreous detachment; SCT, subfoveal choroidal thickness; SRF, subretinal 
fluid.
baseline to 0.30 logMAR (range 0–1.0) (Snellen≅20/40) at the 
final visit (p=0.831). On the other hand, the control group 
demonstrated a loss of one line from a baseline of 0.30 logMAR 
(range 0–1.0) (Snellen≅20/40) to 0.40 logMAR (range 0–3.0) 
(Snellen≅20/50) at the final visit (p=0.031).
Of eyes that achieved early ER, that is, within the first year of 
diagnosis and treatment initiation, the median change in visual 
acuity from baseline to final visit was 0.004 logMAR (range 
−0.50 to 0.20) (p=0.918). The rest of the eyes showed a median 
of 0.05 logMAR (range −0.40 to 0.50) decline in vision between 
baseline and end of study (p=0.03).
Univariate and multivariate Cox regression analyses were 
performed to identify factors for time to achieve ER and the 
time of remission to recurrence. In the multivariate Cox regres-
sion analysis, the presence of isolated IRF at baseline predicted a 
shorter time to achieve ER (2.05- fold faster, HR, 2.05; 95% CI 
1.929 to 4.520; p=0.045) compared with eyes with combined 
IRF and SRF. Multivariate analysis also showed a trend for older 
patients needing longer time to achieve ER (HR, 1.035; 95% 
CI 0.995 to 1.076; p=0.082). There were no significant covari-
ates associated with duration of remission in the Cox regression 
analysis.
Table 2 summarises the results of the logistic regression analysis. 
Eyes with type 3 CNV had an 11.111- fold increased likelihood 
(OR, 0.090; 95% CI 0.021 to 0.382; p=0.001) of achieving ER 
compared with eyes with type 2 CNV. The presence of macular 
atrophy at baseline reduced the probability of achieving ER by 
4.292- fold. Every micrometre decrease in subfoveal choroidal 
thickness increased the likelihood of achieving ER by 0.7% (OR, 
0.993; 95% CI 0.988 to 0.998; p=0.004).
dIsCussIon
In the current study, we report the outcomes of the largest 
cohort of patients with nAMD that achieved ER undergoing 
anti- VEGF therapy by PRN regimen yet presented.
We found that 9.2% of eyes with nAMD may achieve ER 
using a PRN treatment regimen. This is only slightly less than 
our previous report of 11.6% of PRN- treated eyes with nAMD 
achieving remission of over 6 months.22 The CATT extension 
study reported that 14.8% of eyes did not receive any treat-
ment between the end of years 2 and 5, although follow- up 
was incomplete.11 In our study, about 10% of eyes remained 
dry without anti- VEGF injections for a median period of 217 
weeks in the PRN regimen and visual acuity was maintained. 
Moreover, of those achieving an ER, 71% did so within the 
first 3 years since the onset of the disease. Compared with 
fixed monthly and TAE regimens, the PRN schedule may have 
the advantage of permitting cessation of therapy for long 
periods of time in some patients.26 An increased incidence of 
vision- threatening subretinal haemorrhage was associated with 
the PRN treatment strategy compared with TAE.27 Monoc-
ular patients were not included in this study as this group of 
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patients received a fixed dosing schedule of aflibercept given 
every 8 weeks.
Our study showed that the presence of isolated IRF 
predicted a shorter time to achieve ER. Interestingly, IRF 
has been reported to be resolved rapidly with ranibizumab 
compared with SRF. Possible explanations might be that anti- 
VEGF medicine rapidly diminishes active neovascular leakage 
into the retina, and that the intraretinal bioavailability of the 
drug is rapid and efficient.28
We found that eyes with RAP had an 11- fold greater likeli-
hood of achieving ER compared with type 2 CNV. The CATT 
study group reported that eyes with RAP were less likely 
to have fluid at 1 and 2 years after initiation of anti- VEGF 
therapy, but were also more likely to develop retinal atrophy.29 
Multiple reports describe intraretinal cystoid changes with 
fluid as a characteristic optical coherence tomography feature 
of RAP lesions.30 31 Moreover, thinner choroid also increased 
the chance of achieving ER. Prior studies have also suggested 
these characteristics are associated with the ability to discon-
tinue anti- VEGF therapy for over 6 months.22 Interestingly, 
we found that the presence of macular atrophy at baseline 
decreased the probability of achieving ER in this study.
The limitations of this study are its retrospective nature and 
the relatively small study population. We performed the statis-
tical analysis by eye rather than by patient because the rate 
of bilateral inclusion was only 15% of the total population, 
which has a low likelihood of introducing bias. We also did not 
include the last anti- VEGF agent used prior to ER because the 
decision to switch to aflibercept depended on each patient’s 
response to bevacizumab or ranibizumab, and the time at 
which the switch was done varied by clinical response as well. 
It is important to note that we excluded the risk factors that 
would make the results biased, including vitrectomy, PDT and 
laser treatment. We also excluded large subretinal haemor-
rhage to reduce the risk of including poor prognosis eyes.32 In 
AMD, a vision of 20/200 is usually associated with a disciform 
scar or central geographic atrophy. These two conditions being 
present in an eye makes the treatment approach less aggres-
sive. We only included patients with a final visual acuity of 
20/160 or better to ensure that the decision to observe was 
because the disease was truly inactive and not because of less 
aggressive management due to the poor visual prognosis asso-
ciated with a disciform scar or central atrophy.
In conclusion, 9.2% of eyes with nAMD would have 
ER in the PRN regimen. Seventy- one per cent of eyes that 
achieve ER do so within the first 3 years from baseline. Eyes 
with isolated IRF at baseline achieve ER faster. The presence 
of RAP, thinner choroid and absence of macular atrophy at 
baseline are associated with the likelihood of achieving ER. 
Nonetheless, because the majority of patients need ongoing 
treatment, patients should be counselled regarding the need 
for regular monitoring for early detection of recurrence.
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